Stereotaxis, Inc. — Earnings Quality Grade F
STXS · Healthcare
Major red flags
Screening Summary
Management Signals
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO increased by 14 days
AR growth 52.9% exceeds revenue growth 20.3%
Revenue grew 20.3% but CFFO declined -61.1%
Small-cap context: Small-cap revenue/CFFO ratio is sensitive to growth-stage working-capital draws.
Expense Quality
Inventory 14.8% vs COGS 24.2%. Normal
CapEx growth 173.5% is >2x revenue growth 20.3%
SG&A/Gross Profit = 177.4%, exceeds 70%
Gross margin 52.7%, change -1.5pp. Stable
Cash Flow Quality
CFFO < Net Income for 3 consecutive years
Small-cap context: Small-cap CFFO/NI often diverges from working-capital swings, not necessarily manipulation.
FCF is negative ($-0.0B)
Accruals ratio = -15.2%. Low accruals
Cash $0.0B covers debt $0.0B
Balance Sheet Health
Goodwill+Intangibles $0.0B = 54% of equity. Over 50%
Debt/EBITDA = -0.3x. Healthy
Other assets grew 159.8% vs revenue 20.3%
No write-off data
Acquisition Risk
FCF after acquisitions negative for 3 years
Small-cap context: A single acquisition on a small balance sheet can trip serial-acquirer logic.
Goodwill+Intangibles change -8% YoY. Normal
Manipulation Score
M-Score = -2.81 (< -2.22). Unlikely manipulator
Portfolio monitoring
Monitor STXS continuously
The full checks and model details are free to read. Use Watchlist to track your holdings; Pro adds automatic quarterly rescoring, risk-event email alerts, scans up to 50 tickers, and export workflows.
Beneish M-Score
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25